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Background: Pancreatic ductal adenocarcinoma is an aggressive malignancy with late presentation, metastatic
potential and very poor prognosis. Therefore, there is an urgent need for novel diagnostic and prognostic
biomarkers. MicroRNAs are small non-coding RNAs that post-transcriptionally regulate gene expression. Altered
expression of microRNAs has been reported in wide range of malignancies, including pancreatic ductal adenocarcinoma.
The aim of this study was to analyze the expression of selected microRNAs in normal pancreas, chronic pancreatitis and
pancreatic ductal adenocarcinoma tissues and evaluate their diagnostic and prognostic potential.
Findings: Using quantitative real-time PCR, expression levels of 4 microRNAs were examined in 74 tumor tissues,
18 tissues of chronic pancreatitis and 9 adjacent normal tissues and correlated with clinicopathological features of
patients. Expression levels of miR-21, miR-34a and miR-198 were significantly higher, whereas levels of miR-217
were significantly lower in pancreatic ductal adenocarcinomas compared to healthy tissues and tissues of chronic
pancreatitis. Moreover, increased expression of miR-21 and miR-198 was significantly associated with shorter disease
free survival and overall survival.
Conclusions: Our data suggest that altered expression of examined microRNAs is related to neoplastic transformation
and progression of the disease and these microRNAs could serve as diagnostic and prognostic biomarkers for
pancreatic ductal adenocarcinoma.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1373952531543898
Keywords: Pancreatic ductal adenocarcinoma, MicroRNAs, Diagnostic biomarkers, Prognostic biomarkersFindings
Background
Pancreatic cancer (PaC) accounts for 2.2% of all cancers
and is the fourth most common cause of cancer related
deaths [1]. Because of the lack of early symptoms, aggres-
sive growth and early dissemination, most patients are
diagnosed at late stages with advanced distant metastases,* Correspondence: on.slaby@gmail.com
†Equal contributors
1Molecular Oncology II – Solid Cancers, Molecular Medicine, Central
European Institute of Technology, Masaryk University, Brno, Czech Republic
2Department of Comprehensive Cancer Care, Masaryk Memorial Cancer
Institute, Zluty kopec 7, Brno, Czech Republic
Full list of author information is available at the end of the article
© 2015 Vychytilova-Faltejskova et al.; licensee
Creative Commons Attribution License (http:/
distribution, and reproduction in any medium
Domain Dedication waiver (http://creativecom
article, unless otherwise stated.which make their disease surgically inoperable. Moreover,
this type of cancer is known to be highly resistant to
radiotherapy and chemotherapy and has one of the lowest
five-year survival rate among solid cancers [2].
MicroRNAs (miRNAs) are small, non-coding RNAs that
post-transcriptionally regulate gene expression. They can
function as both, oncogenes or tumor suppressors, and
play an important role in the regulation of many biological
processes [3]. They can also serve as new diagnostic and
prognostic biomarkers as well as promising therapeutic
targets [4]. A growing number of studies have proved that
miRNAs regulate the variety of processes involved in the
development, progression and chemoresistance of PaC.BioMed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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217, miR-198 and miR-34a) that have been previously
described to be deregulated in PaC [5-7] was quantified in
tumor tissues of patients with pancreatic ductal adenocar-
cinoma (PDAC), healthy tissues and tissues of chronic
pancreatitis (CP) with the aim to validate their diagnostic
and prognostic potential.
Materials and methods
Patients and tissue samples
Specimens from 74 patients with PDAC (37 males, 37
females) and 18 patients with CP (12 males, 6 females)
who had undergone resection from August 2001 through
April 2012 at the Department of Surgery (Faculty Hospital
Brno, Czech Republic) were used. Moreover, control pan-
creatic tissue samples without signs of inflammation or
dysplastic changes from 9 patients were included. All sub-
jects were of the same ethnicity (European descent). The
ages of patients ranged between 30 and 79 years with a
median of 60.5 years. Written informed consent was ob-
tained from all patients and the study has been approved
by the local Ethical Board.
Extraction of miRNAs
Isolation of total RNA enriched for small RNAs was per-
formed using formalin-fixed paraffin-embedded samples
with more than 90% of cancerous, inflammatory or nor-
mal tissue. All samples were deparaffinized, treated with
DNAse I, proteinase K and RNA extraction was under-
taken using mirVana miRNA Isolation Kit (Ambion Inc,
Austin, TX, USA) according to the manufacturer's instruc-
tions. Concentration and purity of RNA were determined
spectrophotometrically by measuring its optical density
(A260/280 > 2.0, A260/230 > 1.8) using Nanodrop ND-
1000 (Thermo Fisher Scientific, Waltham, MA, USA).
Real-time quantification of miRNAs
Complementary DNA was synthesized from total RNA
according to the TaqMan MicroRNA Assay protocol
(Applied Biosystems, Foster City, CA, USA) using T100™
Thermal Cycler (Bio-Rad, Hercules, CA, USA). Real-
Time PCR was performed according to the standard
protocol using the TaqMan MicroRNA Assay kit and the
Applied Biosystems 7500 Sequence Detection System (both
Applied Biosystems, Foster City, CA, USA).
Data normalization and statistical analysis
The threshold cycle data were calculated by SDS 2.0.1 soft-
ware (Applied Biosystems, Foster City, CA, USA). All real-
time PCR reactions were run in triplicates. The average
expression levels of all measured miRNAs were normalized
using miR-1233 (Assay No. 002768; Applied Biosystems,
Foster City, CA, USA) and subsequently analyzed by the
2-ΔCt method. Statistical differences between the levels ofanalyzed miRNAs were evaluated by non-parametric
Mann-Whitney U-test and Kruskal-Wallis test. Survival
analyses were carried out using the log-rank test and
Kaplan-Meier plots approach. All calculations were per-
formed using GraphPad Prism version 5.00 (GraphPad
Software, San Diego, CA, USA). P-values of less than 0.05
were considered statistically significant.Results
MiRNAs have potential to differentiate PDAC from CP and
normal pancreas
To evaluate the diagnostic potential of 4 selected
miRNAs (miR-21, miR-34a, miR-198 and miR-217), FFPE
samples of 74 PDAC patients, 18 CP patients and 9 non-
tumoral control pancreas were examined by qRT-PCR.
Moreover, RNU48, RNU6B, RNU44, miR-1233 and
miR-1260 were analyzed as potential reference genes.
Using geNorm [8] and NormFinder [9], miR-1233 was
selected to be the most appropriate normalization control.
Using Man-Whitney U-test, significantly higher levels of
miR-198 (P < 0.0001), miR-21 (P = 0.0018), miR-34a
(P = 0.0111) and significantly lower levels of miR-217
(P = 0.0001) were observed in PDAC samples compared
to healthy pancreatic tissue. Moreover, all analyzed
miRNAs had the potential to differentiate PDAC from
CP tissues. Whereas miR-198 (P = 0.0003), miR-21
(P < 0.0001) and miR-34a (P < 0.0001) were significantly
up-regulated, miR-217 (P = 0.0307) was significantly
down-regulated in PDAC samples compared to CP
samples (Figure 1A-D). Subsequently, using ROC
analysis, miR-21 was shown to have the highest capacity
to distinguish between these two groups of samples with
the sensitivity 93%, specificity 72% and AUC= 0.9227. The
results of ROC analyses are summarized in Table 1.MiR-21 and miR-198 can serve as new prognostic
biomarkers for PDAC
To evaluate the prognostic function of analyzed miRNAs,
Kaplan-Meier survival curves have been generated and
compared by log-rank analysis. We have proven that
patients with high levels of miR-21 and miR-198 have
shorter both, disease free survival (DFS; P = 0.0011 for
miR-21; P = 0.0001 for miR-198; Figure 2A-B) and also
overall survival (OS; P = 0.0427 for miR-21; P = 0.0097 for
miR-198; Figure 2D-E). Moreover, when the expression
levels of these two miRNAs were combined, it has been
shown that patients with low levels of both miR-21 and
miR-198 have significantly higher DFS (18.2 months vs. 8
months; Figure 2C) and OS (23.7 months vs. 14.9 months;
Figure 2F) compared to the patients with high levels of
miR-21 and/or miR-198. Expression levels of miR-217 and




Figure 1 Normalized expression of analyzed miRNAs in control pancreatic tissue, CP tissue and PDAC tissue. A) MiR-198 is increased in PDAC
compared to CP tissue (P = 0.0003; CP) and healthy pancreas (P < 0.0001; HP). B) MiR-217 is down-regulated in PDAC compared to CP tissue (P = 0.0307;
CP) and healthy pancreas (P = 0.0001; HP). C) MiR-21 is up-regulated in PDAC compared to CP tissue (P < 0.0001; CP) and healthy pancreas (P = 0.0018;
HP). D) MiR-34a is up-regulated in PDAC compared to CP tissue (P < 0.0001; CP) and healthy pancreas (P = 0.0111; HP). *P < 0.05; **P < 0.001;
***P < 0.0001.
Vychytilova-Faltejskova et al. Diagnostic Pathology  (2015) 10:38 Page 3 of 5Discussion
Successful management and treatment of PDAC patients
remains one of the key challenges in clinical oncology.
Although the early stages of the disease can be treated
surgically, most patients are diagnosed at advanced
stages, when surgical resection is not possible. Moreover,
differential diagnosis of pancreatic lesions is challenging
[10]. Therefore, there is an urgent need for novel diag-
nostic biomarkers that would enable precise differential
diagnosis of pancreatic lesions. In addition, molecular
biomarkers that could serve as prognostic factors would
be very valuable.
MiRNAs have been described to be deregulated in a
variety of solid cancers, including PDAC [11-13]. In thisTable 1 Results of the ROC curve analysis to differentiate
between pancreatic ductal adenocarcinoma and chronic
pancreatitis
miRNA AUCa Cut-off valueb Sensitivity Specificity P-value
miR-21 0.9227 6.3100 93.24% 72.22% < 0.0001
miR-198 0.7748 0.0074 81.08% 72.22% 0.0003
miR-34a 0.8200 1.2400 86.67% 61.11% < 0.0001
miR-217 0.6652 0.1205 64.86% 61.11% 0.0304
aAUC – area under the curve, bCut-off value – expressed as 2-dCt.study, the utility of miR-21, miR-34a, miR-198 and
miR-217 as novel diagnostic and prognostic biomarkers of
PDAC was evaluated. Consistently with the previous data,
significantly increased levels of miR-21 and miR-198
[7,14,15] and decreased levels of miR-217 [7,15,16] have
been observed in PDAC tissue. Despite the fact that
miR-34a is generally described as an important tumor
suppressor [12,17], the expression of this miRNA has
been significantly higher in our PDAC samples compared
to healthy tissue. Therefore, it seems that this miRNA may
have dual functioning as both oncogene and tumor sup-
pressor, depending on the cellular and tumor microenvir-
onment [18].
Importantly, all analyzed miRNAs had a high potential
to differentiate CP from PDAC tissue, therefore, they
might be involved in early events of pancreatic carcino-
genesis. Habbe et al. [19] showed that miR-21 is highly
expressed in early non-invasive intraductal papillary mu-
cinous neoplasms. Further, using in situ hybridization
increased miR-21 expression was found in 79% of PaCs;
however, only 8% of benign pancreas and 27% of CP
expressed this miRNA suggesting its important role in
the development of PaC [20]. MiR-217 was described to
play a crucial role in regulation of acinar-to-ductal meta-
plasia [21], in addition, this miRNA is deregulated not
Figure 2 Kaplan-Meier analysis of DFS and OS based on the expression of miRNAs. A) PDAC patients with high level of miR-198 have shorter
DFS compared to patients with low level of this miRNA (P = 0.0001). B) PDAC patients with high level of miR-21 have shorter DFS compared to
patients with low level of this miRNA (P = 0.0011). C) Combined analysis of miR-21 and miR-198 – PDAC patients with low levels of both miR-21
and miR-198 have longer DFS compared to patients with high levels of miR-21 and/or miR-198 (P < 0.0001). D) PDAC patients with high level of
miR-198 have shorter OS compared to patients with low level of this miRNA (P = 0.0097). E) PDAC patients with high level of miR-21 have shorter
OS compared to patients with low level of this miRNA (P = 0.0427). F) Combined analysis of miR-21 and miR-198 – PDAC patients with low levels
of both miR-21 and miR-198 have longer OS compared to patients with high levels of miR-21 and/or miR-198 (P = 0.0015).
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to non-neoplastic pancreatic tissues [15]. The function of
miR-34a and miR-198 in early development of PaC has
not been described till now, nevertheless, it seems that
miR-21, miR-34a, miR-198 and miR-217 could be used as
tumor markers to distinguish PDAC and its precursors
from a benign lesions.Table 2 The detail results of Kaplan-Meier survival analysis
miRNA 2-dCt value (DFS) Median DFS P-
miR-21 < 22.68 14.2 months 0.
>22.68 7.5 months
miR-198 <0.01208 15.3 months 0.
>0.01208 9.5 months
miR-34a <2.178 9.6 months 0.
>2.178 11.5 months
miR-217 <0.08092 9.6 months 0.
>0.08092 12.2 months
miR-21/miR-198 low levels of both miRNAsa 18.2 months <0
high level of one/both miRNAsc 8 months
alow levels of both miRNAs = level of miR-21 < 22.68 and level of miR-198 < 0.01208
blow levels of both miRNAs = level of miR-21 < 27.15 and level of miR-198 < 0.01393
chigh level of one/both miRNAs = level of miR-21 > 22.68 or/and level of miR-198 >
dhigh level of one/both miRNAs = level of miR-21 > 27.15 or/and level of miR-198 >Given the dismal prognosis of PaC, second aim of this
study was to identify miRNAs with the potential to dif-
ferentiate between patients with good (DFS ≥ 12 months,
OS ≥ 18 months) and poor (DFS < 12 months, OS < 18
months) prognosis. We proved that high levels of
miR-21 and/or miR-198 significantly correlate with poor
prognosis. Concerning miR-21, several studies have beenvalue 2-dCt value (OS) Median OS P-value
0011 <27.15 19.1 months 0.0427
>27.15 15.2 months
0001 <0.01393 22.6 months 0.0097
>0.01393 15.2 months
7186 <2.421 14.9 months 0.9320
>2.421 16.9 months
1716 <0.06097 14.9 months 0.1370
>0.06087 21.5 months
.0001 low levels of both miRNAsb 23.7 months 0.0015
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of this miRNA in PaC [12,20]. Moreover, high levels
of miR-21 were associated with a poor response to
gemcitabine and its levels were increased after the ex-
posure to this drug [22,23]. Concerning miR-198, there
are two contradictory reports analyzing the prognostic
function of this miRNA in PDAC. Whereas Marin-Müller
et al. [24] described high levels of this miRNA to be asso-
ciated with good prognosis, Schultz et al. [7] observed
correlation between over-expression of miR-198 and poor
prognosis. Taken together, our data indicate that miR-21
and miR-198 could be used as potential prognostic
biomarkers in PDAC patients. Importantly, the value of
clinical utility of these miRNAs could be enhanced by
measurement prior to resection in PDAC tissue obtained
by endoscopic ultrasound-guided fine needle aspirates
[25] with the aim to improve the clinical management of
borderline resectable cases and identification the patients
who will benefit most from the surgical resection.
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